Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) is advancing its AI-powered breast CT innovation, the IzoView system, which addresses growing concerns about radiation exposure in cancer screening. Recent studies from the National Institutes of Health highlight increasing worries about radiation from CT scans, and Izotropic's technology aims to optimize breast images while prioritizing dose risk (ibn.fm/NqSvV).
The company's latest piece explores how AI is redefining breast imaging and how the IzoView system was designed for the future. AI-assisted mammography has been shown to boost overall accuracy by about 18% while optimizing diagnostic workflows, according to studies in the U.S. and Europe. However, many AI tools operate on legacy hardware, limiting their potential. Izotropic's IzoView is built as an AI-native platform, integrating a trade-secret reconstruction algorithm that enhances image quality while minimizing radiation dose.
Izotropic's 3D breast CT platform tackles one of the major concerns of cancer screening: radiation exposure. The IzoView system offers a fair price model, making advanced technology more accessible. These updates highlight Izotropic's mission to redefine breast diagnostics using innovation that prioritizes safety, precision, and accessibility. The company believes its strategic position in AI-native design and proprietary algorithms allows it to dominate the future of breast imaging technology.
For more information on Izotropic and its latest news, visit the company's newsroom at ibn.fm/IZOZF.
